NCT01778023View on ClinicalTrials.gov

Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature

PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 17, 2013

Primary Completion Date

December 17, 2014

Study Completion Date

December 17, 2014

Conditions
Growth DisorderIdiopathic Short Stature
Interventions
DRUG

somatropin

A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.

Trial Locations (8)

614-735

Novo Nordisk Investigational Site, Busan

700-721

Novo Nordisk Investigational Site, Daegu

02841

Novo Nordisk Investigational Site, Seoul

03722

Novo Nordisk Investigational Site, Seoul

137-701

Novo Nordisk Investigational Site, Seoul

138-736

Novo Nordisk Investigational Site, Seoul

150-713

Novo Nordisk Investigational Site, Seoul

443-721

Novo Nordisk Investigational Site, Suwon

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY